Filing Flows › Abbott Laboratories (ABT) › Q3 2026 › vs Q3 2025
Abbott Laboratories (ABT) Q3 2026 vs Q3 2025 (year over year)
Abbott Laboratories's revenue rose $1.6B (+14%) from $11.4B in Q3 2025 to $13.0B in Q3 2026. Operating margin 10.4% against 18.1% (-7.7 pts).
Abbott Laboratories, Q3 2026: revenue $13.0B (+14% year over year), operating margin 10.4%, net earnings $920M, operating cash flow $1.7B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 10.4% | 18.1% | -7.7 pts |
| Net margin | 7.1% | 14.5% | -7.4 pts |
| Free cash flow margin | 9.4% | 20.2% | -10.7 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $13.0B | $11.4B | $1.6B | +14% |
| Operating profit | $1.4B | $2.1B | −$699M | -34% |
| Costs & expenses | $11.7B | $9.3B | $2.3B | +25% |
| Pre-tax earnings | $1.2B | $2.2B | −$949M | -44% |
| Other expense, net | $127M | −$123M | $250M | — |
| Cost of revenue | $5.6B | $5.1B | $553M | +11% |
| Research & development | $920M | $766M | $154M | +20% |
| SG&A | $4.3B | $3.1B | $1.2B | +40% |
| Other operating costs | $841M | $420M | $421M | +100% |
| Net earnings | $920M | $1.6B | −$724M | -44% |
| Income tax | $311M | $536M | −$225M | -42% |
| Depreciation & amortization | $1.3B | $791M | $465M | +59% |
| Share-based compensation | $137M | $120M | $17.0M | +14% |
| Working capital & other | $576M | −$232M | $808M | — |
| Operating cash flow | $1.7B | $2.8B | −$1.1B | -38% |
| Free cash flow (OCF − capex) | $1.2B | $2.3B | −$1.1B | -47% |
| Capital expenditures | $513M | $496M | $17.0M | +3% |
Questions
How much did Abbott Laboratories's revenue grow year over year in Q3 2026?
Abbott Laboratories's revenue rose $1.6B (+14%) from $11.4B in Q3 2025 to $13.0B in Q3 2026. Operating margin 10.4% against 18.1% (-7.7 pts).